nach oben

Clinical Rheumatology

Erschienen in:

17.07.2020 | Original Article

The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis

verfasst von: Jiawen Deng, Zachary Silver, Emma Huang, Elena Zheng, Kyra Kavanagh, Jannusha Panicker

Erschienen in: Clinical Rheumatology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction/objectives

The objective of our systematic review and network meta-analysis (NMA) is to investigate which vitamin D and/or calcium regimen would yield the greatest increase in lumbar spine, femoral neck, and total hip bone mineral density (BMD) in adult patients undergoing glucocorticoid therapy.

Method

We performed NMAs based on a prospectively developed protocol. A database search of MEDLINE, EMBASE, Web of Science, CINAHL, CENTRAL and Chinese databases were conducted for relevant randomized controlled trials (RCTs). Outcomes were percentage change in lumbar spine, femoral neck, and total hip BMD from baseline.

Results

We included 16 RCTs containing 1073 eligible patients in our analysis. We found alfacalcidol+calcium to yield the greatest percentage increase in lumbar spine BMD (MD 6.05, 95% credible interval [CrI] − 4.18 to 16.18) compared to no treatment, and calcitriol+calcium to yield the greatest percentage increase in femoral neck BMD (MD 8.46, 95% CrI − 4.74 to 21.51) compared to no treatment. Cholecalciferol+calcium ranked first in terms of its ability to increase total hip BMD; however this finding needs to be interpreted with caution due to low sample sizes in the cholecalciferol+calcium treatment arm. None of the treatment arms ruled out the possibility of no effect for any outcome.

Conclusions

Alfacalcidol and calcitriol were the most efficacious treatment arms for increasing lumbar spine and femoral neck BMD, respectively. Our findings need to be validated by further investigations using larger, better-designed RCTs.

Key Points

•The efficacy of calcium/vitamin D compounds was examined using network meta-analyses.

•Alfacalcidol + calcium yielded the greatest increase in lumbar spine BMD, calcitriol + calcium yielded the greatest increase in femoral neck BMD.

•Future guidelines should place greater emphasis on the efficacy of different vitamin D compounds.

Nur mit Berechtigung zugänglich

Golder V, Hoi A (2017) Systemic lupus erythematosus: an update. Med J Aust 206:215–220. https://doi.org/10.5694/mja16.01229CrossRefPubMed

Becker DE (2013) Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog 60:25–31. https://doi.org/10.2344/0003-3006-60.1.25

Criswell LA, Saag KG, Sems KM, et al (2000) Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev CD001158. https://doi.org/10.1002/14651858.CD001158

The Cochrane Collaboration (1996) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. In: The Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK, p 523

Burns CM (2016) The history of cortisone discovery and development. Rheum Dis Clin N Am 42(1–14):vii–14. https://doi.org/10.1016/j.rdc.2015.08.001CrossRef

Overman RA, Yeh J-Y, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res 65:294–298. https://doi.org/10.1002/acr.21796CrossRef

Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124. https://doi.org/10.1136/ard.2008.092163CrossRefPubMed

Wang M (2005) The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab 2:3. https://doi.org/10.1186/1743-7075-2-3CrossRef

Reid IR (1998) Glucocorticoid effects on bone. J Clin Endocrinol Metab 83:1860–1862. https://doi.org/10.1210/jcem.83.6.4911

10.

Kuchuk NO, Hoes JN, Bijlsma JWJ, Jacobs JWG (2014) Glucocorticoid-induced osteoporosis: an overview. Int J Clin Rheumatol 9:311–326CrossRef

11.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537. https://doi.org/10.1002/art.40137CrossRefPubMed

12.

Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328. https://doi.org/10.1007/s00198-007-0394-0CrossRefPubMed

13.

Hahn TJ, Halstead LR, Baran DT (1981) Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111–115. https://doi.org/10.1210/jcem-52-1-111CrossRefPubMed

14.

Wajchenberg BL, Pereira VG, Kieffer J, Ursic S (1969) Effect of dexamethasone on calcium metabolism and 47Ca kinetics in normal subjects. Acta Endocrinol 61:173–192. https://doi.org/10.1530/acta.0.0610173CrossRef

15.

Huybers S, Naber THJ, Bindels RJM, Hoenderop JGJ (2007) Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol 292:G92–G97. https://doi.org/10.1152/ajpgi.00317.2006CrossRefPubMed

16.

Shi X-M, Chutkan N, W. M, M. C (2012) Mechanism of glucocorticoid-induced osteoporosis: an update. In: Qian X (ed) Glucocorticoids - new recognition of our familiar friend. InTech

17.

Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Wen A, Cheng W, Dobransky J, Sanger S, Grammatopoulos G (2020) Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology. https://doi.org/10.1093/rheumatology/keaa228

18.

Faltinsen EG, Storebø OJ, Jakobsen JC, Boesen K, Lange T, Gluud C (2018) Network meta-analysis: the highest level of medical evidence? BMJ Evid Based Med 23:56–59. https://doi.org/10.1136/bmjebm-2017-110887CrossRefPubMed

19.

Higgins JPT, Thomas J (2019) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons

20.

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784. https://doi.org/10.7326/M14-2385CrossRefPubMed

21.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https://doi.org/10.1136/bmj.b2700CrossRefPubMedPubMedCentral

22.

Haney EM, Huffman LH, Bougatsos C, et al (2016) Screening for lipid disorders in children and adolescents (07-0598-EF-1). Agency for Healthcare Research and Quality (US), Rockville, MD

23.

Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928CrossRefPubMedPubMedCentral

24.

van Valkenhoef G, Lu G, de Brock B et al (2012) Automating network meta-analysis. Res Synth Methods 3:285–299. https://doi.org/10.1002/jrsm.1054CrossRefPubMed

25.

Willink R, Lira I (2005) A united interpretation of different uncertainty intervals. Measurement 38:61–66CrossRef

26.

Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, Guyatt GH (2017) Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews 6:79CrossRefPubMedPubMedCentral

27.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMedPubMedCentral

28.

Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS One 8:e76654. https://doi.org/10.1371/journal.pone.0076654CrossRefPubMedPubMedCentral

29.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629CrossRefPubMedPubMedCentral

30.

Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, del Giovane C, Egger M, Salanti G (2020) CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17:e1003082. https://doi.org/10.1371/journal.pmed.1003082CrossRefPubMedPubMedCentral

31.

Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G (2020) CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 16:1. https://doi.org/10.1002/cl2.1080CrossRef

32.

Puhan MA, Schünemann HJ, Murad MH et al (2014) A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630. https://doi.org/10.1136/bmj.g5630CrossRefPubMed

33.

Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. https://doi.org/10.1136/bmj.d4002CrossRefPubMed

34.

Bernstein CN, Seeger LL, Anton PA et al (1996) A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 10:777–786. https://doi.org/10.1046/j.1365-2036.1996.63205000.xCrossRefPubMed

35.

Li Z, Chines AA, Meredith MP (2004) Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 4:64–74PubMed

36.

Deng J, Abbas U, Chang O, Dhivagaran T, Sanger S, Bozzo A (2020) Antidiabetic and antiosteoporotic pharmacotherapies for prevention and treatment of type 2 diabetes-induced bone disease: protocol for two network meta-analyses. BMJ Open 10:e034741. https://doi.org/10.1136/bmjopen-2019-034741CrossRefPubMedPubMedCentral

37.

Wu T, Li Y, Bian Z, Liu G, Moher D (2009) Randomized trials published in some Chinese journals: how many are randomized? Trials 10:46. https://doi.org/10.1186/1745-6215-10-46CrossRefPubMedPubMedCentral

Titel: The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis
verfasst von: Jiawen Deng
Zachary Silver
Emma Huang
Elena Zheng
Kyra Kavanagh
Jannusha Panicker
Publikationsdatum: 17.07.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 2/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05294-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis

Abstract

Introduction/objectives

Method

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction/objectives

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Differential diagnosis portfolio of a pediatric rheumatologist: eight cases, eight stories

Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience

Cardiac valvular involvement of Takayasu arteritis

Lower risk of primary Sjogren’s syndrome in patients with dengue virus infection: a nationwide cohort study in Taiwan

Patients with asthma have a higher risk of systemic lupus erythematosus: a systematic review and meta-analysis

Multiple nodules under the pericardium in a patient with IgG4-related disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin